w2.cytomed.sg - GDTC Operating profit EBITDA
CytoMed Therapeutics (GDTC) EBITDA reflects R&D-phase dynamics, where the 0.00 mark indicates the level of operating profit. Business growth relies on licensing agreements with institutions without mergers. Revenues are based on the implementation of NK- and gamma-delta T-cell therapies. The viability of the drugs is guaranteed by ultra-fast cold-chain logistics, ensuring the flawless delivery of biomaterials directly to patients.
CytoMed Therapeutics Limited - analytical breakdowns and key metrics (GDTC)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio CytoMed Therapeutics|GDTC - Long-Term Debt to Equity Ratio|Current Liabilities to Capital CytoMed Therapeutics Ltd|GDTC - Company Total Debt|Debt to Book Capital CytoMed Therapeutics|GDTC - Company Long-Term Debt|Short-Term Debt CytoMed Therapeutics|Quick Liquidity Indicator w2.cytomed.sg
- earnings and market ratios statistics:
GDTC - Net Profit|Expected Net Profit CytoMed Therapeutics|GDTC - P/E Multiple|Price to Future Earnings Ratio CytoMed Therapeutics Ltd|GDTC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation CytoMed Therapeutics|GDTC - Operating profit before deduction of amortization|Earnings per share for the last four quarters CytoMed Therapeutics|GDTC - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months w2.cytomed.sg|GDTC - Earnings growth in current year|Expected net earnings per share growth next year CytoMed Therapeutics
Fundamental company valuation:CytoMed Therapeutics GDTC
The CytoMed Therapeutics (GDTC) team in Singapore is directing resources toward developing advanced oncology treatments through clinical trials. By analyzing the company's EBITDA, an investor can track daily operating cash flow, which allows them to differentiate normal seasonality from a critical drop in demand and avoid an unjustified freeze of capital.
Competitors of CytoMed Therapeutics (GDTC)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|Operating profit before deduction of amortization erasca.com ERAS|Delcath Systems - Operating profit before deduction of amortization|Y-mAbs Therapeutics Inc (YMAB) - Profit before interest, taxes and amortization|AURA: Operating profit before deduction of amortization|Candel Therapeutics - Company profit before taxes, interest and amortization|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization SELLAS Life Sciences Group (SLS)|Profit before payment of interest, taxes and amortization Actuate Therapeutics|Operating profit before deduction of amortization Citius Oncology Inc. (CTOR)|Operating profit EBITDA HURA|TARA - Profit before interest, taxes and amortization|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|WHWK: Operating profit before amortization|TCRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CSBR (Champions Oncology)|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CVM: Company profit before taxes, interest and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|RADX: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ARTV|ANL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|Income before deduction of interest, taxes and amortization TPST|Xilio - Operating profit EBITDA|RENB - Operating profit EBITDA|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization KAPA (Kairos Pharma)|OKUR (OnKure Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Curis Corp CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Operating profit EBITDA tharimmune.com (THAR)|Advanced Biomed - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization GNPX (Genprex Inc.)|Calidi Bio - Operating profit EBITDA|Operating income before deduction of amortization sunshinebiopharma.com SBFM|XBIO: Operating profit EBITDA|Operating profit before deduction of amortization salariuspharma.com|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AON (AONC) - Operating income before deduction of amortization|Operating profit EBITDA BGNE|Checkpoint Therapeutics Inc (CKPT) - Operating profit before depreciation charges|Operating profit EBITDA ELEV (Elevation Oncology)|ICAD: Operating profit before amortization|IKNA: Operating profit before deduction of amortization|Notable Labs Ltd - Company profit before taxes, interest and amortization|VIRX: Operating profit EBITDA|Operating profit before deduction of amortization MorphoSys Corporation|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
